Glanbia plc (ISE:GL9)
Ireland
· Delayed Price · Currency is EUR | Market Cap | 4.22B |
| Revenue (ttm) | 3.36B |
| Net Income (ttm) | 156.06M |
| Shares Out | 241.20M |
| EPS (ttm) | 0.62 |
| PE Ratio | 28.36 |
| Forward PE | 14.12 |
| Dividend | 0.43 (2.45%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 257,735 |
| Average Volume | 480,012 |
| Open | 17.55 |
| Previous Close | 17.49 |
| Day's Range | 17.42 - 17.64 |
| 52-Week Range | 9.96 - 17.70 |
| Beta | 0.45 |
| RSI | 57.26 |
| Earnings Date | Aug 6, 2026 |
About Glanbia
Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, capsules, tablets, ready-to-eat bars, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products. In addition, the company engages in the financing business; property and land dealing business; property leasing; provision of business services a... [Read more]
Financial Performance
In fiscal year 2025, Glanbia's revenue was $3.95 billion, an increase of 2.78% compared to the previous year's $3.84 billion. Earnings were $183.30 million, an increase of 11.29%.
Financial numbers in USD Financial StatementsNews
The week ahead in business: ECB decision on interest rates, and CRH, Glanbia and AIB among host of firms to release Q1 figures
The governing council of the European Central Bank (ECB) will meet for two days this week, and will announce its decision on monetary policy at lunchtime on Thursday. However, ECB president Christine ...
Glanbia Earnings Call Transcript: H2 2025
Robust 2025 performance with revenue and volume growth across all segments, despite margin pressure from elevated whey costs. Strategic transformation, portfolio optimization, and capacity expansion underpin medium-term growth targets, with strong cash flow and shareholder returns.
Glanbia Transcript: CMD 2025
Sharpened focus on performance and health nutrition drives ambitious growth targets, with innovation, global expansion, and operational efficiency at the core. Financial guidance includes 5%-7% annual organic revenue growth in performance nutrition, 4%-6% in health & nutrition, and a raised dividend payout ratio.
Glanbia Earnings Call Transcript: Q3 2025
Revenue grew 3.3% year-to-date, led by strong performance in nutrition segments and priority brands. Upgraded full-year guidance reflects robust demand, successful non-core divestments, and continued margin management amid elevated whey costs.
Glanbia to sell Slimfast US to Heartland Food Products group of US
Irish-based nutrition supplement maker Glanbia on Wednesday said it had agreed to sell its weight management brand SlimFast US to Heartland Food Products Group for an undisclosed sum.
Glanbia Earnings Call Transcript: H1 2025
H1 2025 saw resilient results with revenue up 6% and strong Health & Nutrition and Dairy Nutrition growth, offset by Performance Nutrition declines. Upgraded full-year EPS guidance reflects improved trends, while strategic divestments and acquisitions support future growth.
Flax Protein Markets and Companies Analysis Report 2025 with Forecasts to 2029 & 2034 - Featuring Glanbia Nutritionals, Grain Millers, Myprotein, Linwoods Health Foods, Bioriginal Food & Science Corp. and More
Explore the booming Flax Protein Market: projected to soar from $38.54B in 2024 to $56.42B by 2029, driven by the rise in plant-based diets and demand for minimally processed foods. Explore the boomin...
Glanbia shares jump after 'better than feared' first quarter
Shares in nutrition supplement maker Glanbia jumped 10% on Wednesday after analysts pointed to a "better than feared" first quarter performance that allowed the Irish group to maintain its full year e...
Glanbia Earnings Call Transcript: Q1 2025
Revenue grew 7.2% year-over-year, led by strong Health & Nutrition and Dairy Nutrition segments, while Performance Nutrition faced margin pressure from high whey costs and U.S. club channel weakness. Full-year guidance for adjusted EPS and margins is reiterated, with transformation and cost-saving initiatives progressing.
Supplements producer Glanbia's shares dive on profit warning
Shares in nutrition supplement maker Glanbia slid by 15% on Wednesday after it warned that it expects earnings to fall by up to 11% this year, hit by a longer than expected rise in the cost of whey, a...
Glanbia Earnings Call Transcript: H2 2024
Adjusted EPS grew 6.8% and revenue rose 5.8% in 2024, driven by strong demand and portfolio growth. 2025 guidance reflects margin pressure from record whey costs, with mitigation strategies in place and new supply expected to ease costs in 2026.
Glanbia Earnings Call Transcript: Q3 2024
Strong volume growth and robust financials were reported, with Optimum Nutrition and Isopure leading gains. Guidance for 2024 was reiterated, and a business transformation with new segment structure and further share buybacks was announced.
Glanbia Earnings Call Transcript: H1 2024
Strong H1 2024 results with adjusted EPS up 12.4%, driven by Optimum Nutrition and healthy lifestyle brands. Full-year guidance reiterated, but GPN revenue growth range narrowed due to SlimFast and specialty channel softness. Margins upgraded, with continued focus on innovation and shareholder returns.